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Anti-N-methyl-D-aspartate receptor encephalitis is a neurological, autoimmune disorder tightly conceptualized only as recently
as the mid-2000s. It presents itself in a combination of psychiatric, neurological, and autonomic features. We observe a unique
case with probable earlier episode (prior to the mid-2000s conceptualization of the disease) and a later relapse, accompanying a
comprehensive neuropsychological profile tracked after the relapse and subsequent improvement. Neurocognitive findings revealed
residual frontal deficits with mood changes even in the state after plasmapheresis. This case is the first to describe posttreatment
cognition in anti-NMDAR encephalitis after probable serial autoimmune episodes.
1. Introduction
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) ence-
phalitis is a neurological, autoimmune disorder that presents
itself in a combination of psychiatric, neurological, and
autonomic features. Typical representations include generally
acute personality and behavioral changes, memory loss,
hallucinations, dyskinesia, dystonia, and seizures. Significant
portions of the patients, up to 80%, are womenwith amedian
age in the early twenties, and ovarian teratomas and related
autoimmune processes are found in approximately half of
the cases [1–5]. In this case report, we present a patient with
two paroxysms of anti-NMDARencephalitis accompanied by
limited cognitive abilities, frontal deficits, andmood changes.
2. Case Presentation
The patient is a 33-year-old married woman. She managed
the financial aspects and business ventures of the three
companies that she and her husband own. Her social history
was reported normal with no incidents of significant trauma
or substance abuse. Developmental history is unremarkable,
and she completed one and a half years of college. The family
history showed bipolar disorder in one sibling, hypertension,
diabetes, and a strong presence of depression.
Upon records review, documentation revealed that the
patient possibly, or rather probably, experienced her first
episode of autoimmune encephalitis at the age of 24, which
occurred prior to the first conceptualization documented by
Dalmau et al. [3]. This episode was paired with headaches,
hallucinations, delusions, violent outbursts, seizures, and
then a two-month long coma. During this time, hallucina-
tions included seeing a television on the ceiling. She was
hospitalized at an inpatient psychiatric facility, but details of
her clinical diagnoses at the time remain unclear. She then
recovered drastically after receiving a high dose of pred-
nisone and only reported mild to moderate residual deficits.
While no formal neuropsychological measures were given
at the time per report, residual deficits included low-level
math computation, slowed processing speed, and short-term
memory deficits, enough to a level that required supervision
over daily living activities.This continued to resolve for about
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Table 1: Neuropsychological test scores.
Domain Function Measure∗ Standard scores Percentile
Expected
intelligence Estimated premorbid IQ WRAT-4 Reading subtest 86 18
General
intelligence Full scale IQ WAIS- IV 75 5
Verbal memory
Total verbal learning CVLT-II trials 1–5 total 98 45
New learning as distraction to old learning CVLT-II trial B 107 68
Short delay recall CVLT-II short delay 78 7
Long delay recall CVLT-II long delay 85 16
Recognition CVLT-II discriminability 115 84
Visual memory
Total visual learning BVMT-R trials 1–3 total <65 <1
Delay recall BVMT-R delay <65 <1
Recognition BVMT-R Discrimination Index — 1-2
Attention Working memory WAIS-IV Working Memory Index 80 9
Psychomotor speed & attention Trails A 88 21
Higher order
executive skills
Mental flexibility Trails B 58 .3
Response inhibition Stroop C-W 91 27
Novel problem solving
WCST total error 78 7
WCST-64 perseverative responses 86 18
WCST-64 perseverative errors 87 9
WCST-64 categories completed — 2–5
WCST-64 failure to maintain set — —
Speed
Processing speed WAIS-IV Processing Speed Index 86 18
Recognition speed Stroop W 84 14
Stroop C 86 16
Verbal general Verbal comprehension WAIS-IV Verbal Comprehension Index 83 13
Expressive
Semantic fluency Animals 58 .3
Phonemic fluency FAS 58 .3
Naming BNT-2 64 .8
Repetition MAE sentences 71 3
Receptive Comprehension MAE token 106 67
General
perception Perceptual reasoning WAIS-IV Perceptual Reasoning Index 71 3
Visuospatial
construction Visuomotor construction Clock drawing — —
Spatial
perception Visual perception JOLO 79 8
Motor Manual dexterity GD dominant hand 67 1.4
GD nondominant hand 64 .8
∗WRAT-4 Reading = Wide Range Achievement Test, 4th Edition; WAIS-IV = Wechsler Adult Intelligence Scale, 4th Edition; CVLT-II = California Verbal
Learning Test, 2nd Edition; BVMT-R = Brief Visuospatial Memory Test-Revised; Trails A = Trail Making Test Form A; Trails B = Trail Making Test Form B;
StroopC= StroopColor Subtest; StroopW=StroopWord Subtest; StroopC-W=StroopColor-Word Subtest;WCST=WisconsinCard Sorting Test; Animals =
semantic fluency; FAS = phonemic fluency; BNT-2 = Boston Naming Test, 2nd Edition; MAE =Multilingual Aphasia Examination; JOLO = Judgment of Line
Orientation Test; GD = grip dynamometer.
2 years until she was able to drive and care for her children
independently. However, she remained agitated and irritable
compared to her baseline.
The second episode occurred nine years later and was
much more severe. It involved personality changes, persever-
ation in behaviors and speech, impulsive financial behaviors
(e.g., spending over $10,000 on clothes in one week), para-
noia, psychosis, and aggressive outbursts. She also had dress-
ing apraxia, and her psychosis included visual hallucinations
of monsters and demons, melting ceilings, delusions of her
children being trapped under the bathroom tiles, and the
belief that she had to free them using only her fingernails. She
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was under restraint during her inpatient stay for aweek due to
aggressive outbursts. She also developed status epilepticus 4
times, which were treated with conventional IV antiepileptic
drugs.
Video EEG showed epileptic activity in the right fron-
toparietal region.The remainder of the workup was negative,
includingMRI, CT, PET, transvaginal US, and LP.MRIs of the
brain and pelvis were both negative (pelvic MRI was initiated
to rule out ovarian teratoma). CSF was unrevealing including
T. pallidum,West Nile, IgG, albumin, cell ct/protein/glucose,
cultures, cryptococcal Ag, India ink, HSV PCR, and TB.
Laboratory testing by Mayo Clinic revealed that the serum
anti-NMDA antibodies were negative, but CSF anti-NMDA
antibodies with repeat testing were found to be positive.
Treatment included bilateral salpingo-oophorectomy (but
no ovarian teratoma was found), IVIG transfusion, and
plasmapheresis. She was later switched to rituximab infusion
and also received medications for psychosis and seizures.
Final diagnosis was documented as anti-NMDA-receptor
encephalitis without teratoma. A neuropsychological evalua-
tion occurred after treatment. It showed numerous cognitive
deficits such as impairments in visual memory, mental
flexibility, expressive language, visuospatial skills, and motor
dexterity (see Table 1). The most significant problems were
present in verbal fluency (semantic and phonemic fluency,
both <1st percentile), mental flexibility (<1st percentile),
and elevated depression and anxiety. She continues to have
compromised cognitive status along with residual frontal
deficits and mood changes. She and her guardian provided
consent for this case study to be published.
3. Discussion
In anti-NMDAR encephalitis, antibodies are directed
towards the NR1 subunit of the NMDA receptor causing a
depletion ofNMDA receptors [1, 4, 6, 7].The lack of receptors
causes neuropsychiatric symptoms, attributable to ovarian
teratomas and autoimmune processes in approximately half
of the cases [2–4, 6, 8]. Recognizing the symptom complex
is crucial to diagnosis [7]. Commonly, patients develop a
multistage illness that progresses from psychiatric symptoms
to more extreme global symptoms [1]. Up to half of the
women diagnosed with anti-NMDAR encephalitis have an
underlying ovarian teratoma [3, 8].
Treatment involves immunosuppression with steroids
and intravenous administration [1, 4, 7, 9]. Many patients
recover well after appropriate treatment [10]. While it is
thought that there is a higher prevalence of anti-NMDAR
encephalitis, data on posttreatment cognitive states remain
rather limited [11, 12]. This case revealed residual frontal
deficits with mood changes in the context of anti-NMDAR
encephalitis. This case is the first to describe posttreatment
cognition in anti-NMDAR encephalitis after probable serial
autoimmune episodes.
4. Conclusion
Anti-N-methyl-D-aspartate receptor encephalitis is a neuro-
logical, autoimmune disorder tightly conceptualized only as
recently as the mid-2000s. It presents itself in a combination
of psychiatric, neurological, and autonomic features. This
case was a unique case with probable earlier episode (prior to
the mid-2000s operationalization of the disease) and a later
relapse, accompanying a comprehensive neuropsychological
profile tracked after the relapse and subsequent improvement.
Neurocognitive findings revealed residual frontal deficits
with mood changes even in the state after plasmapheresis,
and these deficits do not appear to associate neatly with
structural brain damage visible in imaging (or lack thereof),
as clinical symptoms were likely the sequelae of a more global
neuroinflammatory damage that occurred. This case is the
first to describe posttreatment cognition in anti-NMDAR
encephalitis after probable serial autoimmune episodes.
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